Dr. Manish A. Shah on BBI608 in the Treatment Paradigm for Gastrointestinal Cancers
Shah says as more treatments become available, oncologists need to consider the order in which they give treatments to patients with gastric and gastroesophageal junction cancer.
Manish A. Shah, MD, medical oncologist, Bartlett Associate Professor of GI Oncology, Weill Cornell Medical Center at NewYork-Presbyterian Hospital, discusses how BBI608 might fit into the treatment paradigm for gastric and gastroesophageal junction cancer. Shah says as more treatments become available, oncologists need to consider the order in which they give patients treatments. He adds that not all gastric cancers are the same, so identifying which cancers would be best treated by a PD-1 inhibitor and which would be best treated by a stem cell inhibitor is crucial.
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL
December 18th 2024During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.
Read More
